Want to see BHVN full AI Analyst Report?
BHVN Stock Chart & Stats
$14.38
-$0.33(-2.25%)
At close: 4:00 PM EDT
$14.38
-$0.33(-2.25%)
Day’s Range― - ―
52-Week Range$7.48 - $18.57
Previous CloseN/A
Volume1.72M
Average Volume (3M)2.92M
Market Cap
$1.92B
Enterprise Value$2.27K
Total Cash (Recent Filing)$267.87M
Total Debt (Recent Filing)$297.04M
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Nov 17, 2026EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.64
Shares Outstanding151,043,780
10 Day Avg. Volume2,955,393
30 Day Avg. Volume2,917,704
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)23.33
Price to Sales (P/S)0.00
P/FCF Ratio-1.99
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.00Price Target Upside39.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.73
Revenue Forecast (FY)$58.33M
Bulls Say, Bears Say
Bulls Say
Non-dilutive Licensing ProceedsThe Kv7 licensing agreement provides substantial non-dilutive funding while preserving milestone and royalty participation. Partnering commercialization with an established epilepsy company can reduce Biohaven’s funding burden, extend runway, and create recurring economics if the platform succeeds.
Advanced Epilepsy PipelineA fully enrolled pivotal study represents meaningful development progress and reduces one major execution hurdle for BHV-7000. Continued dosing and a scheduled data readout preserve a potentially important catalyst for validating the lead program and supporting future partnering or commercialization economics.
Improving Net Loss TrendAlthough Biohaven remains deeply unprofitable, the sequential improvement in net loss suggests some moderation in expenses or development spending. If sustained, this trend could improve capital efficiency and extend the benefit of licensing proceeds across the broader neuroscience and specialty-care pipeline.
Bears Say
Extreme Balance-sheet LeverageThe very small equity cushion relative to debt leaves Biohaven financially vulnerable despite prospective licensing proceeds. High leverage can constrain investment choices, increase refinancing exposure, and raise the likelihood that future funding needs could affect shareholders through dilution or additional obligations.
Heavy And Worsening Cash BurnLarge recurring operating and free-cash-flow deficits indicate that Biohaven’s research model continues to consume substantial capital before commercial revenue is established. Persistent burn increases dependence on licensing, financing, or other external funding and can limit the company’s ability to advance multiple programs simultaneously.
FDA Partial Clinical HoldThe partial clinical hold introduces regulatory and execution uncertainty around Biohaven’s lead epilepsy asset, even though dosing continues for randomized patients and the 303 timeline is currently unaffected. Further findings could still delay enrollment, alter development plans, or weaken the program’s commercial value.
Biohaven Ltd. News
BHVN FAQ
What was Biohaven Ltd.’s price range in the past 12 months?
Biohaven Ltd. lowest stock price was $7.48 and its highest was $18.57 in the past 12 months.
What is Biohaven Ltd.’s market cap?
Biohaven Ltd.’s market cap is $1.92B.
When is Biohaven Ltd.’s upcoming earnings report date?
Biohaven Ltd.’s upcoming earnings report date is Nov 17, 2026 which is in 64 days.
How were Biohaven Ltd.’s earnings last quarter?
Biohaven Ltd. released its earnings results on Aug 10, 2026. The company reported -$0.91 earnings per share for the quarter, missing the consensus estimate of -$0.761 by -$0.149.
Is Biohaven Ltd. overvalued?
According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued.
Does Biohaven Ltd. pay dividends?
Biohaven Ltd. does not currently pay dividends.
What is Biohaven Ltd.’s EPS estimate?
Biohaven Ltd.’s EPS estimate is -0.61.
How many shares outstanding does Biohaven Ltd. have?
Biohaven Ltd. has 151,043,780 shares outstanding.
What happened to Biohaven Ltd.’s price movement after its last earnings report?
Biohaven Ltd. reported an EPS of -$0.91 in its last earnings report, missing expectations of -$0.761. Following the earnings report the stock price went down -0.344%.
Which hedge fund is a major shareholder of Biohaven Ltd.?
Currently, no hedge funds are holding shares in BHVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biohaven Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (39.08% Upside)
$20.00 (39.08% Upside)
Blogger Sentiment
Bullish
BHVN Sentiment 69%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 7.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-32.64%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Biohaven Ltd.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
BHVN Stock 12 Month Forecast
Average Price Target
$20.00
▲(39.08% Upside)
Technical Analysis
Ownership Overview
10.74% Insiders
11.94% Mutual Funds
34.87% Other Institutional Investors
34.16% Public Companies and
Individual Investors